Capturing circulating tumour cells in the blood would appear to offer women the chance of earlier detection of ovarian cancer, which is often diagnosed late in the course of the disease.
The Medical University of Vienna recently reported highly convincing patient data in support of the use of Angle’s Parsortix system in the detection of ovarian cancer.The university will now lead, in collaboration with Angle, a clinical study of the use of the Parsortix system as a clinical application in the routine detection and treatment of ovarian cancer patients.
The multicentre clinical study will be undertaken in collaboration with other members of the European Network for Translational Research in Ovarian Cancer (EUTROC) and the Tumour Bank Ovarian Cancer Network (TOC) from Austria, Belgium, Germany and the UK. It is expected to take 18 months to complete. Assuming the clinical study confirms the recent patient study results,the Parsortix system will help to inform detection of ovarian cancer and clinical decision-making in its treatment.
The patient study was undertaken under Angle’s collaboration agreement with the Ludwig Boltzmann Cluster ‘Translational Oncology’ led by the head of the interdisciplinary Molecular Oncology Group at the Medical University of Vienna, Professor Robert Zeillinger. The study utilised RNA markers developed in Vienna to analyse the cells harvested by Angle’s Parsortix system.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
Register
